Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameSipai Health
Stock Code00314
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities經營特藥藥房業務、醫生研究協助及健康保險服務。特藥藥房業務為中國最大私營特藥藥房;醫生研究協助為最大腫瘤現場管理組織(SMO);健康保險服務透過健康服務提供商網絡服務大量會員。
Listing Date2022-12-23
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)廣東省廣州市廣州國際生物島螺旋大道51號官洲生命科學創新中心A塔26樓11–13室
Business Address (Hong Kong)香港灣仔皇后大道東248號大新金融中心40樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.medbankshealthtech.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 18.60 / shares
Offer Price RangeFinal offer price only, no range
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer Period2022-12-12 to 2022-12-15
Global Offering Shares9,919,400 shares
HK Public Offer Shares (Initial)992,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)8,927,400 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO763,025,314 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 184,500,840

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 1.26B
Est. Threshold HK$ 9.69B
Analysis Result HK market cap below threshold, need +670%

Valuation & Financials

Market Cap (at Offer Price)HK$ 14,192,270,840
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損約人民幣3,748.5百萬元
Period-End Cash BalanceTo be extracted
Listing Expenses~HK$ 64,100,840
Listing Expenses / Funds Raised~34.74%
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201920202021
Revenue 1,039,0112,699,6473,473,930
Cost of sales -957,207-2,512,787-3,190,481
Gross profit 81,804186,860283,449
Other income and gains, net 7,00434,80851,069
Selling and distribution expenses -116,032-183,450-291,461
Administrative expenses -219,462-361,242-670,021
Operating profit -273,637-379,914-695,699
Net finance costs -2,877-3,527-3,688
Share of associates and JVs 586-65137
Profit before tax -596,020-1,040,850-3,747,678
Income tax expense -38-51-1,179
Profit for the year -596,071-1,042,029-3,748,503
Profit attributable to owners -594,595-1,042,781-3,740,455
Balance Sheet
Item 201920202021
Cash and cash equivalents 199,1101,628,021535,849
Trade and bills receivables 38,71744,602171,195
Inventories 211,186279,931269,035
Total current assets 958,6532,292,1562,488,243
Total assets 1,151,1062,478,5982,892,819
Total current liabilities 337,419613,245830,800
Total liabilities 2,158,0434,270,2458,323,729
Total equity -1,006,937-1,791,647-5,430,910
Equity attributable to owners -1,010,590-1,796,652-5,429,224
Income Statement
Balance Sheet
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 25.0
First Day OpenHK$ 23.7
First Day Change34.41%
First Day Volume2174600.0
First Day Turnover52611300.0
Use of Proceeds
1、約87%或約104.8百萬港元預計將用于業務擴張; 2、約13%或約15.6百萬港元預期將用于技術研發及提升技術基礎設施。

Underwriting Syndicate

Joint Sponsors (2)
Morgan Stanley Asia Limited CE AAD291 海通国际资本有限公司 CE ADQ859
Overall Coordinators (2)
Morgan Stanley Asia Limited CE AAD291 海通国际证券有限公司 CE AAF806
Joint Bookrunners (2)
Morgan Stanley Asia Limited CE AAD291 海通国际证券有限公司 CE AAF806
Joint Lead Managers (5)
Morgan Stanley Asia Limited CE AAD291 海通国际证券有限公司 CE AAF806 富途证券国际(香港)有限公司 CE AZT137 迈时资本有限公司 CE BNO600 I WIN SECURITIES LIMITED CE BJB315

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman馬旭廣—
Company Secretary任娜、曾穎雯—
No director data available.

Major Shareholders

Major Shareholders & Holdings馬旭廣先生及李繼先生(一致行動人)合計持有約21.43%股權;騰訊集團持有約27.41%股權。
About this page

This page shows Sipai Health (00314) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect